Examination of ketamine-induced deficits in sensorimotor gating and spatial learning

Physiology and Behavior

Volumn 107, Issue 3, 2012, Pages 355-363

  Sabbagh, Jonathan J ^a   Heaney, Chelcie F ^a   Bolton, Monica M ^a   Murtishaw, Andrew S ^a   Kinney, Jefferson W ^a  

^a UNIVERSITY OF NEVADA   (United States)

Author keywords

Ketamine; NMDA antagonist; Spatial learning; Water maze

Indexed keywords

KETAMINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; MALE; MAZE TEST; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SENSORIMOTOR NEUROPATHY; SENSORY GATING; SPATIAL LEARNING; SPATIAL MEMORY; TASK PERFORMANCE;

EID: 84867220180     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2012.08.007     Document Type: Article

References (73)

1. Green CJ, Knight J, Precious S, Simpkin S. Ketamine alone and combinedwith diazepam or xylazine in laboratory animals: a 10 year experience. Lab Anim 1981;15:163-70.
2. Bergman SA. Ketamine: reviewof its pharmacology and its use in pediatric anesthesia. Anesth Prog 1999;46:10-20.
3. CohenSP, LiaoW, GuptaA, Plunkett A. Ketamine inpainmanagement. AdvPsychosom Med 2011;30:139-61.
4. Murrough JW. Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther 2012;91:303-9.
5. Wolff K, Winstock AR. Ketamine: from medicine to misuse. CNS Drugs 2006;20: 199-218.
6. Becker A, Peters B, Schroeder H, Mann T, Huether G, Grecksch G. Ketamineinduced changes in rat behaviour: a possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:687-700.
7. Chrobak JJ, Hinman JR, Sabolek HR. Revealing past memories: proactive interference and ketamine-induced memory deficits. J Neurosci 2008;28:4512-20.
8. Moosavi M, Yadollahi Khales G, Rastegar K, Zarifkar A. The effect of sub-anesthetic and anesthetic ketamine on water maze memory acquisition, consolidation and retrieval. Eur J Pharmacol 2012;677:107-10.
9. Pietersen CY, Bosker FJ, Postema F, Fokkema DS, Korf J, den Boer JA. Ketamine administration disturbs behavioural and distributed neural correlates of fear conditioning in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1209-18.
10. Smith JW, Gastambide F, Gilmour G, Dix S, Foss J, Lloyd K, et al. A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology (Berl) 2011;217:255-69.
11. Gonzalez-Burgos G, Hashimoto T, Lewis DA. Alterations of cortical GABA neurons and network oscillations in schizophrenia. Curr Psychiatry Rep 2010;12:335-44.
12. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996;16:19-30.
13. Bullock WM, Cardon K, Bustillo J, Roberts RC, Perrone-Bizzozero NI. Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am J Psychiatry 2008;165:1594-603.
14. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA. Ionotropic glutamate receptors and expression ofN-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 2000;157:1141-9.
15. Eastwood SL, Harrison PJ. Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. Schizophr Res 2005;73:159-72.
16. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999;156:1646-9.
17. Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry 1978;135: 1081-4.
18. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999;20:201-25.
19. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitiveNMDA antagonist, ketamine, in humans. psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
20. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001;25:455-67.
21. Braff DL, Grillon C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 1992;49:206-15.
22. Cilia J, Hatcher P, Reavill C, Jones DN. (+/-)Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics. J Psychopharmacol 2007;21:302-11.
23. Imre G, Fokkema DS, Den Boer JA, Ter Horst GJ. Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Res Bull 2006;69:338-45.
24. Ludewig K, Geyer MA, Vollenweider FX. Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biol Psychiatry 2003;54: 121-8.
25. Swerdlow NR, Bakshi V, Waikar M, Taaid N, GeyerMA. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology (Berl) 1998;140:75-80.
26. Swerdlow NR, Braff DL, Taaid N, GeyerMA. Assessing the validity of an animalmodel of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994;51:139-54.
27. Asada H, Kawamura Y, Maruyama K, Kume H, Ding R, Ji FY, et al. Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65) maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures. Biochem Biophys Res Commun 1996;229:891-5.
28. Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003;23:6315-26.
29. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed bymicroarray analysis of gene expression in prefrontal cortex. Neuron 2000;28:53-67.
30. Reynolds GP, Zhang ZJ, Beasley CL. Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity. Brain Res Bull 2001;55:579-84.
31. Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, Knable MB. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 2005;57:252-60.
32. Lewis DA, Glantz LA, Pierri JN, Sweet RA. Altered cortical glutamate neurotransmission in schizophrenia: evidence from morphological studies of pyramidal neurons. Ann N Y Acad Sci 2003;1003:102-12.
33. Lewis DA, Hashimoto T. Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons. Int Rev Neurobiol 2007;78:109-31.
34. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999;33:523-33.
35. Volk DW, Lewis DA. Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiol Behav 2002;77:501-5.
36. Woo TU, Miller JL, Lewis DA. Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Am J Psychiatry 1997;154:1013-5.
37. Volman V, Behrens MM, Sejnowski TJ. Downregulation of parvalbumin at cortical GABA synapses reduces network gamma oscillatory activity. J Neurosci 2011;31:18137-48.
38. Duncan GE, Moy SS, Knapp DJ, Mueller RA, Breese GR. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res 1998;787:181-90.
39. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17:2921-7.
40. Nakao S, Nagata A, Miyamoto E, Masuzawa M, Murayama T, ShinguK. Inhibitory effect of propofol on ketamine-induced c-fos expression in the rat posterior cingulate and retrosplenial cortices is mediated by GABAA receptor activation. Acta Anaesthesiol Scand 2003;47:284-90.
41. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007.
42. Gao XM, Hashimoto T, Tamminga CA. Phencyclidine (PCP) and dizocilpine (MK801) exert time-dependent effects on the expression of immediate early genes in rat brain. Synapse 1998;29:14-28.
43. Gass P, Herdegen T, Bravo R, Kiessling M. Induction and suppression of immediate early genes in specific rat brain regions by the non-competitive N-methyl-D-aspartate receptor antagonist MK-801. Neuroscience 1993;53:749-58.
44. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003;117:697-706.
45. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007;27: 11496-500.
46. Hampton RY, Medzihradsky F, Woods JH, Dahlstrom PJ. Stereospecific binding of 3H-phencyclidine in brain membranes. Life Sci 1982;30:2147-54.
47. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8.
48. Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepamin humans. Psychopharmacology (Berl) 1998;135:213-29.
49. Zhang Y, Behrens MM, Lisman JE. Prolonged exposure to NMDAR antagonist suppresses inhibitory synaptic transmission in prefrontal cortex. J Neurophysiol 2008;100: 959-65.
50. Behrens MM, Ali SS, Dao DN, Lucero J, Shekhtman G, Quick KL, et al. Ketamineinduced loss of phenotype of fast-spiking interneurons is mediated by NADPHoxidase. Science 2007;318:1645-7.
51. Kinney JW, Davis CN, Tabarean I, Conti B, Bartfai T, Behrens MM. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci 2006;26:1604-15.
52. Vutskits L, Gascon E, Tassonyi E, Kiss JZ. Effect of ketamine on dendritic arbor development and survival of immature GABAergic neurons in vitro. Toxicol Sci 2006;91:540-9.
53. Vutskits L, Gascon E, Potter G, Tassonyi E, Kiss JZ. Low concentrations of ketamine initiate dendritic atrophy of differentiated GABAergic neurons in culture. Toxicology 2007;234:216-26.
54. Couture SM, Penn DL, Roberts DL. The functional significance of social cognition in schizophrenia: a review. Schizophr Bull 2006;32(Suppl. 1):S44-63.
55. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology (Berl) 2003;169: 215-33.
56. Folley BS, Astur R, Jagannathan K, Calhoun VD, Pearlson GD. Anomalous neural circuit function in schizophrenia during a virtual Morris water task. Neuroimage 2010;49:3373-84.
57. Hanlon FM, Weisend MP, Hamilton DA, Jones AP, Thoma RJ, Huang M, et al. Impairment on the hippocampal-dependent virtual morris water task in schizophrenia. Schizophr Res 2006;87:67-80.
58. Wesierska M, Macias-Gonzalez R, Bures J. Differential effect of ketamine on the reference and working memory versions of the morris water maze task. Behav Neurosci 1990;104:74-83.
59. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001;156:117-54.
60. Canal NM, Gourevitch R, Sandner G. Non-monotonic dependency of PPI on temporal parameters: differential alteration by ketamine and MK-801 as opposed to apomorphine and DOI. Psychopharmacology (Berl) 2001;156:169-76.
61. Ma J, Leung LS. The supramammillo-septal-hippocampal pathway mediates sensorimotor gating impairment and hyperlocomotion induced by MK-801 and ketamine in rats. Psychopharmacology (Berl) 2007;191:961-74.
62. Sandner G, Canal NM, Brandao ML. Effects of ketamine and apomorphine on inferior colliculus and caudal pontine reticular nucleus evoked potentials during prepulse inhibition of the startle reflex in rats. Behav Brain Res 2002;128:161-8.
63. Battaglia M, Abbruzzese M, Ferri S, Scarone S, Bellodi L, Smeraldi E. An assessment of the Wisconsin card sorting test as an indicator of liability to schizophrenia. Schizophr Res 1994;14:39-45.
64. Shad MU, Tamminga CA, Cullum M, Haas GL, Keshavan MS. Insight and frontal cortical function in schizophrenia: a review. Schizophr Res 2006;86:54-70.
65. Sullivan EV, Mathalon DH, Zipursky RB, Kersteen-Tucker Z, Knight RT, PfefferbaumA. Factors of the Wisconsin card sorting test as measures of frontal-lobe function in schizophrenia and in chronic alcoholism. Psychiatry Res 1993;46:175-99.
66. Day LB, Weisand M, Sutherland RJ, Schallert T. The hippocampus is not necessary for a place response but may be necessary for pliancy. Behav Neurosci 1999;113: 914-24.
67. CunninghamMO, Hunt J, Middleton S, LeBeau FE, Gillies MJ, Davies CH, et al. Regionspecific reduction in entorhinalgamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness. J Neurosci 2006;26:2767-76.
68. Zhang Y, Yoshida T, Katz DB, Lisman JE. NMDAR antagonist action in thalamus imposes delta oscillations on the hippocampus. J Neurophysiol 2012;107:3181-9.
69. Bolton MM, Heaney CF, Sabbagh JJ, Murtishaw AS, Magcalas CM, Kinney JW. Deficits in emotional learning and memory in an animal model of schizophrenia. Behav Brain Res 2012;233:35-44.
70. Wass C, Archer T, Palsson E, Fejgin K, Klamer D, Engel JA, et al. Effects of phencyclidine on spatial learning and memory: nitric oxide-dependent mechanisms. Behav Brain Res 2006;171:147-53.
71. Kondziella D, Brenner E, Eyjolfsson EM, Markinhuhta KR, Carlsson ML, Sonnewald U. Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure. Neuropsychopharmacology 2006;31:1880-7.
72. Lopez-Gil X, Babot Z, Amargos-Bosch M, Sunol C, Artigas F, Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2007;32:2087-97.
73. Rowland LM, Astur RS, Jung RE, Bustillo JR, Lauriello J, Yeo RA. Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology 2005;30:633-9.